GovChime
Notice ID: 487470c8ad234ddcbd76ae24b4a94754Combined Synopsis/Solicitation

Vela Diagnostics Inc. test kits

Archived on September 13, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
3:00 PM UTC−04:00
Posted
August 26, 2024
Notice type
Combined Synopsis/Solicitation
NAICS
325414: Biological Product (except Diagnostic) Manufacturing
Agency
Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION

Notice details

Office
CDC OFFICE OF ACQUISITION SERVICES
Place of performance
Atlanta, GA, 30329
Last updated
Dec 4, 2025

Identifiers

Solicitation number
HCWBB-2024-00236
Notice ID
487470c8ad234ddcbd76ae24b4a94754

Description

The Centers for Disease Control (CDC) and Prevention intends to award a sole source firm fixed price purchase order to Vela Diagnostics, Inc. for test kits for the Sentosa SQ HIV-1 Genotyping Assay, which is an automation method, carrying out whole lab procedures from sample to result report, including HIV viral extraction, RT-PCR, library preparation, next generation sequencing, data analysis, and next generation sequencing (NGS) HIV drug resistance (HIVDR) reports. Vela Dianotistics, Inc. is the only company that manufactures these test kits that are FDA approved. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 41 U.S.C. 3304(a)(1).. Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is NOT a request for competitive quotations; however, all quotations/responses received within three (3) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to contract specialist at ZTB8@cdc.gov by COB 29 August 2024.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:HCWBB-2024-00236
  1. Combined Synopsis
  1. Combined SynopsisCurrentAug 26, 2024

    Vela Diagnostics Inc. test kits

    Notice 487470c8ad234ddcbd76ae24b4a94754 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Amendment 5 is being issued to re-open the solicitation and proceed with source selection activities. Reinstate Jennifer Gartzke as the point of contact. The attached SF30 contains additional information.
-Solicitation02/15/2026
NOTICE OF INTENT – SOLE-SOURCE ACQUISITION Notice No.: The National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), intends to award a Firm-Fixed-Price Purchase Order to Creative Biolab Inc. for culture all cells and differentiate them, expand their cell populations to more than 20 million, collect them, verify cell count, and send them back to us. Description of the Requirement The primary objective of this study is to sequence and analyze the 4q35 locus on Chromosome 4 for several years. This locus is a gene-poor and extremely long (>100K) region of DNA that consists of many repetitive sequences which makes sequencing and analysis extremely difficult. To sequence this locus using Nanopore Sequencing technology. To expand the number of samples for our experiment, we looked for a company that can handle numerous cell lines and follow the protocol that we provide. Creative Biolabs is the only company/research institute that has been able to perform differentiation within 3 months and has the ability to follow our protocol with numerous cell lines. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Only Creative Biolabs was willing to follow our exact protocol and had the logistical capacity to handle the large number of cell lines that we need to analyze, which is vital to research at the National Institute of Environmental Health Sciences. Response Information This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required preventive maintenance and remedial repair services for the specified instrument and meet all applicable technical and operational requirements. The Government will review timely submissions to determine whether another responsible source is capable of satisfying the requirement and whether a competitive acquisition is appropriate. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source can satisfy the requirement. Capability statements must be submitted electronically to verne.griffin@nih.gov no later than 9:00 a.m. EDT on November 13, 2026. Please reference Notice No. 75N98027Q00053 in the subject line of the submission.
-Pre-Solicitation11/12/2026
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers.
-Combined Synopsis11/18/2026
See attached Sources Sought Notice.
-Market Research10/28/2026
Emergency Pharmacy Order of DigiFAB
-Sole Source / J&AOpen

Additional Details

Solicitation Number

HCWBB-2024-00236

Archive Date

Sep 13, 2024

Office Address

ATLANTA, GA, 30333